The biopharmaceutical industry has a voracious appetite for new technologies that increase productivity and improve performance,
a point confirmed by BioPlan Associates' annual survey on bioprocessing trends and innovation (1).
BIOPROCESSING INNOVATIONS IN DEMAND
When asked about average budget changes from 2009–2012, those surveyed reported the highest budget increases were for new
technologies to improve efficiencies and costs for downstream production (an average 6.4% increase) and for upstream production
(an average 6.0% increase). For new products, the largest portion of respondents cited disposable bags and connectors (40.0%),
followed by probes and sensors, (36.1%), chromatography products (32.2%), bioreactors (31.7%), and purification products (28.9%)
(see Figure 1). Much of the interest in improved sensors, bioreactor, purification, and other equipment involves single-use
applications. Only 10% of respondents wanted new stainless-steel equipment. In services, upstream process-development services
topped the list.
Figure 1: Select new product and service areas of interest, 2010–2012.
The survey showed that a common cause for dissatis-faction with current single-use bioreactors, liners, and other equipment
is they are not robust enough. Single-use equipment is still not adaptable to the more extreme mixing, heat, and other conditions
involved with most microbial systems (e.g., E. coli and yeast).
When asked to rate the factors responsible for creating bioprocessing improvements in the past 12 months, the largest portion
(72.6%) cited "overall better control of processes," followed by "improved downstream production operations," and "use of
VENDOR'S FOCUS ON R&D
To evaluate how well vendors' R&D match industry needs, the BioPlan survey asked about budget changes in 2012. Vendor respondents
reported an average 1.9% increase in basic R&D for product development, a 2.4% increase for hiring new staff, a 4.3% gain
in sales budgets, and a 3.4% uptick in capital-equipment purchases.
Survey data show vendors concentrating much of their R&D on improved and new single-use equipment (see Figure 2). The largest
portion (46.2%) report working on bioprocess development/optimization services and bioprocess modeling, followed by disposable/single-use
bioreactors and consumables, single-use bags and films, filtration, and chromatography products. Other examples of vendor
R&D include: animal-free media components; bioreactor control; chromatography alternatives to Protein A; cell-line optimization;
sensors and probes; culture-media optimization services; alternative mammalian-cell expression systems; monitoring systems;
culture-media supplements; controller systems; impurities detection; bacterial expression systems; lyophilization; testing/assay
services (e.g., raw materials, glycosylation, viral clearance, cell lines); and packaging materials.
Figure 2: The top six new technologies being worked on by vendors, 2010 – 2012.